TMEM97 and PGRMC1 do not mediate sigma-2 ligand-induced cell death.
Journal
Cell death discovery
ISSN: 2058-7716
Titre abrégé: Cell Death Discov
Pays: United States
ID NLM: 101665035
Informations de publication
Date de publication:
2019
2019
Historique:
received:
28
11
2018
revised:
19
12
2018
accepted:
08
01
2019
entrez:
1
2
2019
pubmed:
1
2
2019
medline:
1
2
2019
Statut:
epublish
Résumé
Sigma-2 receptors have been implicated in both tumor proliferation and neurodegenerative diseases. Recently the sigma-2 receptor was identified as transmembrane protein 97 (TMEM97). Progesterone receptor membrane component 1 (PGRMC1) was also recently reported to form a complex with TMEM97 and the low density lipoprotein (LDL) receptor, and this trimeric complex is responsible for the rapid internalization of LDL. Sigma-2 receptor ligands with various structures have been shown to induce cell death in cancer cells. In the current study, we examined the role of TMEM97 and PGRMC1 in mediating sigma-2 ligand-induced cell death. Cell viability and caspase-3 assays were performed in control, TMEM97 knockout (KO), PGRMC1 KO, and TMEM97/PGRMC1 double KO cell lines treated with several sigma-2 ligands. The data showed that knockout of TMEM97, PGRMC1, or both did not affect the concentrations of sigma-2 ligands that induced 50% of cell death (EC
Identifiants
pubmed: 30701090
doi: 10.1038/s41420-019-0141-2
pii: 141
pmc: PMC6349905
doi:
Types de publication
Journal Article
Langues
eng
Pagination
58Subventions
Organisme : NCI NIH HHS
ID : R01 CA163764
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM008076
Pays : United States
Déclaration de conflit d'intérêts
The authors declare that they have no conflict of interest.
Références
Br J Cancer. 2000 Mar;82(6):1223-32
pubmed: 10735510
Cancer Res. 2002 Jan 1;62(1):313-22
pubmed: 11782394
Cancer Res. 2005 Oct 1;65(19):8975-83
pubmed: 16204071
Eur J Pharmacol. 2005 Nov 21;525(1-3):8-17
pubmed: 16289030
Int J Oncol. 2007 Jan;30(1):91-5
pubmed: 17143516
BMC Cancer. 2007 Dec 11;7:223
pubmed: 18070364
Autophagy. 2008 May;4(4):487-99
pubmed: 18305408
Cell Metab. 2009 Jul;10(1):63-75
pubmed: 19583955
Nat Commun. 2011 Jul 05;2:380
pubmed: 21730960
Br J Cancer. 2012 Feb 14;106(4):693-701
pubmed: 22251921
J Exp Clin Cancer Res. 2012 May 02;31:41
pubmed: 22551149
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
J Surg Oncol. 2013 Apr;107(5):456-62
pubmed: 22996179
Med Oncol. 2013 Mar;30(1):324
pubmed: 23254963
J Med Chem. 2013 Sep 26;56(18):7137-60
pubmed: 23734634
Cell Physiol Biochem. 2014;33(5):1359-68
pubmed: 24853233
PLoS One. 2014 Nov 12;9(11):e111898
pubmed: 25390368
PLoS One. 2014 Nov 12;9(11):e111899
pubmed: 25390692
Tumour Biol. 2015 Sep;36(10):8231-8
pubmed: 26002575
EBioMedicine. 2015 Oct 19;2(11):1806-13
pubmed: 26870805
Oncotarget. 2016 Jun 7;7(23):33529-41
pubmed: 27244881
Hum Mol Genet. 2016 Aug 15;25(16):3588-3599
pubmed: 27378690
Pharmacol Res. 2017 Mar;117:67-74
pubmed: 28007569
BMC Cancer. 2017 Jan 13;17(1):51
pubmed: 28086830
J Exp Clin Cancer Res. 2017 Jan 17;36(1):14
pubmed: 28095907
Adv Exp Med Biol. 2017;964:49-61
pubmed: 28315264
Proc Natl Acad Sci U S A. 2017 Jul 3;114(27):7160-7165
pubmed: 28559337
Sci Rep. 2018 Nov 15;8(1):16845
pubmed: 30443021
Biochemistry. 1973 Jul 3;12(14):2612-9
pubmed: 4711469
Life Sci. 1995;57(4):PL57-62
pubmed: 7603301
Cell Growth Differ. 1993 Sep;4(9):715-22
pubmed: 7694637
Eur J Pharmacol. 1994 Jun 15;268(1):9-18
pubmed: 7925616
Cancer Res. 1997 Jan 1;57(1):156-61
pubmed: 8988058
J Pharmacol Exp Ther. 1976 Jun;197(3):517-32
pubmed: 945347